Is coagulopathy a common consequence of a Vipera berus bite? A retrospective single centre study
More details
Hide details
Department of General Surgery John Gawlik Hospital, Sucha Beskidzka, Poland
First Department of General, Oncological & Gastroenterological Surgery Jagiellonian University Medical College, Cracow, Poland
Jagiellonian University Medical College, Cracow, Poland
Corresponding author
Katarzyna Elżbieta Dyląg-Trojanowska   

Department of General Surgery John Gawlik Hospital, Sucha Beskidzka, Stara Huta 28e, 32-500 Chrzanów, Poland
Ann Agric Environ Med. 2018;25(4):630-634
The Vipera berus (common viper) is the only species of venomous snake found in Poland. The aim of this study was to determine to what extent coagulopathy has occurred as a post-bite complication.

Material and methods:
The medical records of 138 adult patients in the Sucha Beskidzka hospital with the diagnosis of snake bite between 2001–2014 were retrospectively analyzed. Demographic, clinical and laboratory data were collected. Antivenom was given to all patients, except one, with snake bites, but laboratory test were taken prior to administration of antivenom. Obtained results were compared to those of the control group, composed of 176 adults hospitalized in the same period for an elective laparoscopic cholecystectomy.

The mean platelet count in the study group was 239.94×109/L (SD=56.56) and 248.77×109/L (SD=57.82) in the control group. In 98% of the study group and 100% of the control group the platelet value (PLT) fell within laboratory norms (130 to 420×109/L), 2 patients after snake bites had a PLT lower than normal, and thrombocytosis was not observed in either group. A reference range of 0.85–1.3 INR below normal was found in 2 patients in the study group and 15 from the control group, while values above the normal range were found in 8 patients (6.7%) from the snake bite group and no patients from the control group. In the study group, the INR ranged from 0.78–1.43 with a mean of 1.046 (SD=0.14), while in the control group the range was from 0.79–1.28, with a mean of 0.95 (SD=0.08). There was a significant difference in INR between the study and control groups (p<0.0001).

The bite from V. berus does not result in severe thrombocytopenia, with only a moderate increase in INR values observed in about 7% of patients.

Gutiérrez JM, Williams D, Fan HW, Warrell DA. Snakebite envenoming from a global perspective: Towards an integrated approach. Toxicon. 2010; 56(7): 1223–1235.
Isbister GK. Snakebite doesn’t cause disseminated intravascular coagulation: coagulopathy and thrombotic microangiopathy in snake envenoming Semin Thromb Hemost. 2010; 36(4): 444–451.
Ciszowski K, Modła A. [Envenoming by common viper (V. berus) – subject still exists…]. Przegl Lek. 2004; 61(4): 427–432. Polish.
Wierzbicka I, Prokopowicz D, Kołakowska R, Panasiuk A. [Snake bites]. Przegl Epidemiol. 1997; 51(3): 359–362. Polish.
Ostapiuk J. Odpowiedź podsekretarza stanu w Ministerstwie Środowiska – z upoważnienia ministra – na interpelację nr 26993 w sprawie udzielenia odszkodowań za zwierzęta hodowlane śmiertelnie ukąszone przez żmije. (access 2017.07.05).
Kośmider J, Nawrocka M, Jobda M, Jasińska K. [Variable habitat preferences of the common European adder Vipera berus observed in the provinces of Mazovia and Lublin (Poland)]. Studia i Materiały CEPL w Rogowie 2013; 36(3):184–194 (access 2017.07.05).
Kalana M, Isbister GK. Current Treatment for Venom – Induced Consumption Coagulopathy Resulting from Snakebite. PLoS Negl Trop Dis 2014; 8(10): e3220.
Berling I, Isbister GK. Hematologic Effects And Complications Of Snake Envenoming. Transfus Medi Rev. 2015; 29(2): 82–89.
Bocian A, Urbanik M, Hus K, Łyskowski A, Petrilla V, Andrejcakova Z, et al. Proteome and Peptidome of Vipera berus berus Venom. Molecules 2016; 21:1398. doi:10.3390/molecules21101398.
Czajka U, Wiatrzyk A, Lutyńska A. [Mechanism of Vipera berus venom activity and the principles of antivenom administration in treatment]. Przegl Epidemiol. 2013; 67(4): 729 -733. Polish.
Karlson-Stiber Ch, Salmonson H, Persson H. A nationwide Study of Vipera Berus Bites during one Year – epidemiology and morbidity of 231 cases. Clin Toxicol. 2006; 44(1): 25–30.
Jollivet V, Hamel JF, de Haro L, Labadie M, Sapori JM, Cordier L, et al. European viper envenomation recorded by French poison control centers: A clinical assessment and management study. Toxicon. 2015; 108: 97–103.
Grönlund J, Vuori A, Nieminen S. Adder bites. A report of 68 cases. Scand J Surg. 2003; 92(2): 171–174.
Menon JC, Joseph JK, Jose MP, Dhananjaya BL, Oommen OV. Clinical Profile and Laboratory Parameters in 1051 Victims of Snakebite from a Single Centre in Kerala, South India. J Assoc Physicians India. 2016; 64(8): 22–29.
Marinov I, Atanasov VN, Stankova E, Duhalov D, Petrova S, Hubenova A. Severe coagulopathy after Vipera ammodytes ammodytes snakebite in Bulgaria: a case report. Toxicon. 2010; 56(6):1066–1069.
Garkowski A, Czupryna P, Zajkowska A, Pancewicz S, Moniuszko A, Kondrusik M, et al. Vipera berus bites in Eastern Poland – a retrospective analysis of 15 case studies. Ann Agric Environ Med. 2012; 19(4): 793–797.
Magdalan J, Trocha M, Merwid-Lad A, Sozański T, Zawadzki M. Vipera berus bites in the Region of Southwest Poland – a clinical analysis of 26 cases. Wilderness Environ Med. 2010; 21(2): 114–119.
Bart G, Pineau S, Biron C, Connault J, Artifoni M. Bilateral Pulmonary Embolism Following a Viper Envenomation in France: A Case Report and Review. Medicine (Baltimore). 2016; 95(19): e2798.
Isbister GK, Duffull SB, Brown SG. Failure of antivenom to improve recovery in Australian snakebite coagulopathy. QJM. 2009; 102: 563–568.
Boels D, Hamel JF, Bretaudeau Deguigne M, Harry P. European viper envenomings: Assessment of Viperfav™ and other symptomatic treatments. Clin Toxicol (Phila). 2012; 50(3): 189–96.
Journals System - logo
Scroll to top